JT-001
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- JT-001
- Molecular weight
- 402.48
- Structure (SMILES)
- O=C(Nc1c2c(cc3c1CCC3)CCC2)NS(=O)(=O)c1cnn2c1OCCC2
- 5h pyrazolo 5 1 b 1 3 oxazine 3 sulfonamide n 1 2 3 5 6 7 hexahydro s indacen 4 yl amino carbonyl 6 7 dihydro
- 5H-Pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide, N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-6,7-dihydro-
- clarithromycin jt001
- jt 001
- Jt-001
- JT-001
- jt001
- Jt001
- JT001
- JT001 200mg Bid
- JT001 400mg Bid
- JT001 600mg Bid
- CAS registry numbers
- 2238819-65-1
- ChEMBL ID
- CHEMBL5219660
- InChIKey
- KWSGPJCQWZMUQM-UHFFFAOYSA-N
- PubChem compound IDs
- 135240787
- FDA ingredient codes (UNII)
- 43K4X7JG75
- First in class
- No
- Orphan designation
- No
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT05101135
- NCT05242042
- NCT05279235
- NCT05341609
- NCT05582629
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 102.32
- Calculated partition coefficient (ALogP)
- 2.15
- Calculated partition coefficient (XLogP)
- 3
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 28
- Molecular formula
- C19H22N4O4S
- Monoisotopic mass
- 402.13617637
- Natural product
- No
- Recorded assays
- 40
- Active assays
- 4
Active assay types
- Confirmatory
Solubility
- Median
- 102,000
- Mean
- 102,000
- Minimum
- 102,000
- Maximum
- 102,000
- Unit
- nM
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Oral bioavailability
- Median
- 23
- Mean
- 23.25
- Minimum
- 17
- Maximum
- 30
- Unit
- %
- Assays
- 4
- Standard deviation
- 6.70199
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Plasma protein binding
- Median
- 98.6
- Mean
- 97.56
- Minimum
- 95.5
- Maximum
- 99.1
- Unit
- %
- Assays
- 5
- Standard deviation
- 1.67422
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- PPB
Related records
Trials (8)
- A Real-World Study of JT001 for COVID-19
- Efficacy and Safety of JT001 (VV116) Compared With Favipiravir
- Efficacy and Safety of JT001 (VV116) Compared With Paxlovid
- Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets
- JT001 (VV116) for the Early Treatment of COVID-19
- JT001 (VV116) for the Treatment of COVID-19
- The Mass Balance Study of [14C]JT001
- To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
In development for (2)
- COVID-19 Phase 3
- Type 2 diabetes mellitus Phase 3